Abstract
There is much activity on this front. For the selective estrogen receptor modifiers (SERMs), there is long term data on raloxifene and recent data on new SERMs – (lasofoxilene and arzoxifene). An individual patient overview will be given to update both short-term (< 5 yrs) and long term (5–10 y) efforts.
Results from the MAP3 trial on the aromatase inhibitor exemestane has recently been reported and additional long term data on prevention of contralateral tumours in the adjuvant ATAC trial using anastrozole will be reviewed, as well as the current situation of the IBIS II prevention trial with anastrozole.
There is much interest in nonhormonal agents for breast cancer prevention including metformin, bisphosphonates, aspirin, and the NSAIDs, which will all be reviewed.
Citation Information: Cancer Prev Res 2011;4(10 Suppl):ED04-01.